Longevity drugs · comparison
Rapamycin vs metformin: the comparison stopped being close
Rapamycin vs metformin stopped being an even contest in 2025, when a meta-analysis of 167 studies split the pair; rapamycin had already extended mouse lifespan by 9% to 14% (per Harrison and colleagues, 2009).
Which one has better animal evidence?
Strong human evidence The 2025 Aging Cell meta-analysis reached an unusually clean conclusion: dietary restriction and rapamycin both increased lifespan across vertebrate species and in both sexes, and metformin did not, despite a 5.8% mean gain reported for it in model organisms (per Keys and colleagues, 2025).[1] Independent expert commentary emphasized the same split.[2]
Do 167 animal studies favor one drug?
Yes, rapamycin, the most useful fact in the rapamycin vs metformin debate: pooled across eight vertebrate species (per Ivimey-Cook and colleagues, 2025), only one of the two reliably lengthened life. Most longevity coverage still treats them as interchangeable.
For a reader weighing either drug, that means the animal case belongs to rapamycin alone. Metformin's appeal has to rest on something else: its human safety record and its benefits for people with metabolic disease.
- What this does not say
- Animal data with high heterogeneity and significant publication bias, per the authors; no human lifespan endpoint exists for either drug.
What is better than rapamycin?
In that analysis, only dietary restriction matched it.[1] Rapamycin extended mouse lifespan in the Interventions Testing Program even when started late in life.[3] [4] The same program has not produced an equivalent metformin result, a meaningful negative from a program built to catch irreproducible claims.
Show the numbers as a table
| Measure | Value |
|---|---|
| Rapamycin, mice | 9% to 14% |
| Metformin, model organisms | 5.8% mean |
Which one has better human evidence?
Metformin, provided you are careful about what the evidence is for. Its safety profile over decades of continuous use is genuinely known. That is a category of knowledge rapamycin simply does not have at longevity doses.
What metformin does not have is a longevity result. Its geroprotective case rests largely on observational analyses suggesting people with diabetes taking it had mortality comparable to non-diabetic controls, an intriguing finding with obvious confounding problems.[5]
- The trial designed to test it properly has been discussed for years without running.[6]
- Rapamycin's human file is thinner still: a systematic review of human use found real biological effects and no lifespan endpoint anywhere.[7]
Nobody's going to make enough money off of rapamycin to do the clinical trials that really should be done.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 2009 | Rapamycin in mice | Lifespan up, late start |
| 2016 | TAME rationale | Metformin trial proposed |
| 2019 | Exercise trial | Metformin blunts gains |
| 2024 | Human review | No lifespan endpoint |
| 2025 | Meta-analysis | Only rapamycin works |
Do rapamycin and metformin work the same way?
No, although the two are often introduced together as calorie restriction mimetics, which obscures how differently they act. Rapamycin binds FKBP12 and inhibits mTORC1 directly and potently. Metformin works upstream, largely by activating AMPK and inhibiting mitochondrial complex I, which can lower mTOR signaling as a downstream consequence.
One drug switches off the pathway; the other nudges a network that eventually touches it. Our explainer on how mTOR inhibition actually works covers the first mechanism in detail.
Does metformin blunt the benefits of exercise?
Early / mixed evidence It did in a 12-week randomized trial in older adults, which found that metformin blunted the improvement in insulin sensitivity and muscle mitochondrial adaptation produced by exercise training.[8] The people taking it got less out of the same workouts than the people on placebo.
For someone with type 2 diabetes that trade is usually still worth making. For a metabolically healthy person taking it speculatively for longevity while also training, it is an argument that deserves to be on the table, and it very rarely is.
Rapamycin vs metformin: which carries more risk?
Rapamycin, on current evidence: metformin's risks over years of use are small and known, while rapamycin's are larger and partly unknown.
Why are people stopping taking metformin?
Metformin's problems are well mapped: gastrointestinal upset that causes many people to stop, vitamin B12 depletion over years, and lactic acidosis as a rare event largely confined to significant kidney impairment. Everything on that list is known, monitorable and reversible.
What rapamycin adds to the risk ledger
Rapamycin is an immunosuppressant with a dose-dependent adverse event profile drawn mostly from transplant medicine, plus an unquantified long-term risk in healthy people. We go through that separation in what actually changes at longevity doses. On risk, the rapamycin vs metformin ledger is lopsided in both directions: more known harm on one side, more unknown harm on the other.
Can you take them together?
People do, usually on the reasoning that hitting two nutrient-sensing pathways is better than one. No trial has tested the combination against either drug alone for any aging-related outcome, and the two push glucose handling in opposite directions, which makes the metabolic result of combining them genuinely unpredictable without monitoring.
Our page on what the metformin longevity evidence shows sets out that side of the case in full.
Which drug has the stronger case overall?
Neither wins outright: rapamycin has the stronger aging evidence in living animals, pooled from 167 papers in the 2025 meta-analysis, while metformin has the safety record you would want before twenty years of use.[1] They answer different questions, and the meta-analysis made the first answer clearer, not murkier.
Neither answer is the one people actually want, which is a compound proven to extend healthy human life. Rapamycin vs metformin is a comparison between an animal result without human confirmation and a human safety record without a longevity result. Our main evidence guide lays out what would need to change for that to stop being true.
Frequently asked questions
Does metformin interfere with training?
It did in one controlled test. In a 12-week randomized trial of older adults doing aerobic training, metformin blunted the gain in insulin sensitivity and muscle mitochondrial adaptation seen on placebo (per Konopka et al., 2019). The volunteers did not have diabetes, so the result speaks to healthy people taking it speculatively.
Does combining them change what needs monitoring?
It widens it. The two push glucose handling in opposite directions, so anyone combining them under a prescriber is watching both drugs' known effects at once, with no trial describing what the combined pattern should look like.
Do people on metformin look younger?
There is no evidence for that. The observational finding that generated the interest was about mortality in diabetics compared with matched non-diabetics, not appearance. Nothing in the trial literature measures how anyone looks.
Can I take metformin for 20 years?
Many people with type 2 diabetes have. That is precisely its advantage in this comparison: the long-term safety picture is genuinely known, including the main real risk, which is vitamin B12 depletion that goes unnoticed unless someone checks.
What happens when you take metformin for years?
Most people tolerate it, with gastrointestinal upset the usual reason for stopping early. Over years, B12 levels can fall enough to matter, which is why periodic testing is standard. Lactic acidosis is the rare serious risk and is largely confined to people with significant kidney impairment.
Which one has better animal evidence?
Rapamycin, decisively. The 2025 meta-analysis of 167 studies found it extended lifespan across vertebrate species in both sexes, while metformin did not produce a consistent effect. The rigorous mouse testing program has also repeatedly failed to show a metformin lifespan benefit.
Which one has better human evidence?
Metformin, by a wide margin, but not for longevity. It has enormous human data as a diabetes drug and essentially no controlled human data as a geroprotector. The trial that would test that has been proposed for years and has not run.
How long would a trial need to run to compare them on aging?
Years, not weeks. The only placebo-controlled trial of weekly rapamycin in healthy adults ran 48 weeks, and a lifespan or multi-disease endpoint needs far longer follow-up, which is why no head-to-head comparison exists.
Can either drug's effect on aging be seen on a routine blood test?
Only indirectly. Glucose, HbA1c and lipids show metabolic effects and side effects, but no validated blood marker shows aging slowing, so an improved panel does not tell you either drug is extending life.
Can you take rapamycin and metformin together?
Some people do, and there is no trial testing the combination for any longevity outcome. Both affect glucose handling in opposite directions, which makes the combined effect on metabolism hard to predict without monitoring.
Which one is easier to get?
Metformin, without contest. It is cheap, widely prescribed for diabetes and prediabetes, and familiar to every physician. Rapamycin requires a prescriber willing to write it off-label for an unapproved purpose.
Is metformin useless for longevity then?
Not established would be more accurate than useless. Its case rests on observational data and disease-risk reduction in people with metabolic dysfunction, which is a real benefit for that group. What it lacks is evidence of slowing aging in people who are metabolically healthy.
Why do they get compared at all?
Because both are cheap, approved, well-characterized drugs that appeared in longevity research at the same time, and because both were framed as calorie restriction mimetics. The framing turned out to fit one of them considerably better than the other.
What would settle the question?
A properly powered human trial with an age-related disease endpoint, of the kind proposed for metformin and now beginning for rapamycin in specific populations. Until one reports, both cases rest on animals and inference.
References
8 sources, all link-checked; oldest check
- Rapamycin, not metformin, mirrors dietary restriction-driven lifespan extension in vertebrates. Ivimey-Cook ER et al. Aging Cell 2025;e70131 (cited 10).Meta-analysis pooling 167 studies across vertebrate species; dietary restriction and rapamycin extended lifespan consistently, metformin did not.Publisher blocks automated checks · last tried Sep 15, 2026
- Expert reaction to a meta-analysis looking at the effect of rapamycin, metformin and dietary restriction on lifespan in vertebrates. Science Media Centre, June 2025.Independent expert commentary noting the result held across all vertebrate species analyzed and in both sexes.Verified Sep 15, 2026
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Harrison DE et al. Nature 2009;460:392–395.9–14% mouse lifespan extension started mid-life.Verified Sep 15, 2026
- Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Miller RA et al. Aging Cell 2014;13(3):468–477.Higher doses produced larger lifespan gains; effect size differs by sex.Publisher blocks automated checks · last tried Sep 15, 2026
- Metformin as a tool to target aging. Barzilai N et al. Cell Metabolism 2016;23(6):1060–1065.Rationale for the TAME (Targeting Aging with Metformin) trial.Publisher blocks automated checks · last tried Sep 15, 2026
- Emerging uncertainty on the anti-aging potential of metformin. Keys MT et al. 2025 (cited 20).Recent review re-examining the metformin longevity case, including the 5.8% mean lifespan increase reported in model organisms and the confounding in the human observational data.Publisher blocks automated checks · last tried Sep 15, 2026
- Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Konopka AR et al. Aging Cell 2019;18(1):e12880.Publisher blocks automated checks · last tried Sep 15, 2026
- Targeting aging with rapamycin and its derivatives in humans: a systematic review. Lee DJW et al. The Lancet Healthy Longevity 2024.Systematic review, cited 189 times.Publisher blocks automated checks · last tried Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.